Bristol Myers Squibb Faces $6.7 Billion Lawsuit Over Celgene Deal: Key Takeaways and Financial Analysis

Bristol Myers Squibb (BMY) faces a $6.7 billion lawsuit over its acquisition of Celgene. The lawsuit alleges the company delayed drug approvals to avoid payments to Celgene shareholders. The judge allowed certain claims to proceed, including breach of contract. BMY derives 70% of its sales from the US and exhibits strong profitability metrics, but its Altman Z-Score indicates potential financial stress. The stock has a P/E ratio of 16.61 and a recommendation score of 2.7.